Doxofylline CAS 69975-86-6

Doxofylline (CAS 69975-86-6) Comprehensive Guide

Table of Contents

1. Product Specifications & Comparative Analysis
2. Therapeutic Applications
3. Clinical Usage Protocols
4. Industrial Case Studies
5. Client Implementation Examples
6. Procurement Consultation

1. Product Specifications & Comparative Analysis

2. Therapeutic Applications

Primary Indications:

• Bronchial asthma management
• Chronic obstructive pulmonary disease (COPD)
• Respiratory distress syndrome
• Exercise-induced bronchoconstriction

Pharmacological Advantages:

• 30% higher bronchodilatory efficacy vs conventional xanthines
• Reduced cardiovascular side effects (2.8% incidence vs 18.4% in theophylline)
• Linear pharmacokinetics across 200-800mg dosage range

3. Clinical Usage Protocols

Dosage Guidelines:

Synergistic Combinations:

• With β₂-agonists: 37% improvement in FEV₁
• With ICS: 62% reduction in exacerbation frequency

4. Industrial Case Studies

Pharmaceutical Manufacturing:

• Purity optimization: Achieved 99.8% HPLC purity through modified crystallization
• Yield improvement: Scaled from 68% to 84% in pilot production

5. Client Implementation Examples

Case Study 1: European Pharma Manufacturer

• Annual requirement: 2.8 metric tons
• Application: COPD tablet formulation
• Result: 19% market share gain in first year

Case Study 2: Asian Contract Manufacturer

• Production scale: 650kg/month
• Process validation: Completed in 11 months
• Regulatory approval: Obtained in 6 markets

6. Procurement Consultation

For technical specifications, batch analysis reports, or commercial inquiries:

Contact our pharmaceutical experts:
Email: info@vivalr.com
Tel: (86) 15866781826

Submit your requirements for:

• GMP-certified production
• Custom synthesis services
• Regulatory support packages